Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

VitaNova Life Sciences (YJGJ) Current Assets (2017 - 2026)

VitaNova Life Sciences (YJGJ) has disclosed Current Assets for 8 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets rose 85.59% year-over-year to $2.3 million, compared with a TTM value of $2.3 million through Oct 2025, up 85.59%, and an annual FY2025 reading of $2.3 million, up 89.15% over the prior year.
  • Current Assets was $2.3 million for Q4 2025 at VitaNova Life Sciences, up from $2.2 million in the prior quarter.
  • Across five years, Current Assets topped out at $2.3 million in Q4 2025 and bottomed at $8728.0 in Q2 2023.
  • Average Current Assets over 5 years is $863652.8, with a median of $964356.0 recorded in 2024.
  • The sharpest move saw Current Assets crashed 73.97% in 2023, then skyrocketed 13567.03% in 2024.
  • Year by year, Current Assets stood at $31693.0 in 2021, then grew by 11.03% to $35190.0 in 2022, then tumbled by 75.2% to $8728.0 in 2023, then surged by 14322.69% to $1.3 million in 2024, then skyrocketed by 85.59% to $2.3 million in 2025.
  • Business Quant data shows Current Assets for YJGJ at $2.3 million in Q4 2025, $2.2 million in Q3 2025, and $2.3 million in Q2 2025.